Dr. Nicholas B. Cline
Allergy & Immunology (Allergy & Immunology Physician)
- Medicare participating
At a glance
- Medical school
- Mercer University School of Medicine (2019)
- Years since graduation
- 7
- In the NPI registry since
- 2019
- Medicare patients seen, 2024
- 254
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2019Medical school: Mercer University School of Medicine
- 2019Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
TN license 71631
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Fort Loudoun Medical Center Lenoir City, TN
Medical groups
- Allergy Associates, PA (74 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 254
- Services billed
- 1,174
- Patients’ average age
- 73
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 13 companies reported 84 payments worth $2,043 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $454 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $449 |
| Amgen Inc. | $191 |
| Genentech USA, Inc. | $155 |
| GlaxoSmithKline, LLC. | $139 |
| Genzyme Corporation | $135 |
| Novartis Pharmaceuticals Corporation | $109 |
| Ars Pharmaceuticals Operations, Inc. | $106 |
| Food and Beverage | $2,009 |
|---|---|
| Education | $34.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Amgen Inc. Jul 29, 2025 | Education in-kind | $34.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $27,018 in research payments for these studies, mostly to the institutions running them.
- A multicentre, randomized, double-blind, placebo-controlled, dose find
GlaxoSmithKline, LLC. - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.